The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

In the final years of her husband's life, BJ Carter finally learned details of her husband's life he'd never remembered.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.